Updates in chronic graft-versus-host disease.

Area of Science:

• Hematopoietic stem cell transplantation
• Immunology
• Oncology

Background:

• Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for hematologic malignancies.
• Chronic graft-versus-host disease (GVHD) remains a significant challenge, representing the primary cause of late morbidity and mortality post-HCT.
• Current treatment strategies for chronic GVHD are limited, with corticosteroids being the mainstay, often leading to prolonged therapy and substantial adverse effects impacting long-term quality of life.

Observation:

• Chronic GVHD presents with heterogeneous and pleomorphic symptoms, complicating diagnosis and management.
• Significant progress has been made in defining diagnostic criteria, severity assessment, and response evaluation for chronic GVHD in clinical trials over the past two decades.
• Understanding the underlying biologic mechanisms of chronic GVHD pathogenesis has spurred the investigation of novel immunomodulatory and targeted therapeutic approaches.

Findings:

• Multi-institutional collaborations and pharmaceutical support are crucial for developing new therapies.
• Therapeutic development is increasingly guided by robust biologic rationale and rigorous clinical trials with well-defined endpoints.
• Several promising novel agents targeting specific pathways involved in chronic GVHD are nearing approval.

Implications:

• These advances offer hope for improved prevention and treatment strategies for chronic GVHD.
• The development of targeted therapies may reduce the long-term adverse effects associated with current treatments.
• Enhanced understanding of GVHD biology is critical for optimizing patient outcomes and quality of life after allogeneic HCT.